Valuation dashboard for Neurocrine Biosciences, Inc. (NBIX) with P/E 20.31, P/B 3.92, EV/EBITDA 15.87 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
Analysis Summary
Neurocrine Biosciences, Inc. reported revenue of $2.86B in the most recent fiscal year, growing at a 5-year CAGR of 22.3%. Net income reached $478.6M, with a 3.3% 5-year CAGR.
Trailing-twelve-month margins: gross margin 98.0%, operating margin 23.4%, net margin 20.9%.
At the current price of $141.84, NBIX trades at a P/E of 20.31 and an ROE of 21.13%. Market capitalisation stands at $14.3B, placing it among large-cap names.
Balance sheet quality for NBIX: current ratio of 3.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 20.31 |
| Price / Book | 3.92 |
| EV / EBITDA | 15.87 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $295.59 |
| vs Current Price | +108.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences, Inc. | $14.3B | 20.31 | 3.92 | 21.1% |
| HOLX | Hologic, Inc. | $17.0B | 30.28 | 3.25 | 11.1% |
| SMMT | Summit Therapeutics Inc. | $13.4B | 21.33 | -204.3% | |
| COO | The Cooper Companies, Inc. | $11.1B | 19.42 | 1.32 | 6.9% |
| ICLR | ICON Public Limited Company | $12.4B | 37.77 | 1.33 | 2.5% |
| TEM | Tempus AI, Inc. | $13.8B | 30.99 | -49.9% | |
| SNN | Smith & Nephew plc | $11.2B | 17.45 | 2.16 | 12.2% |
| ELAN | Elanco Animal Health Incorporated | $11.2B | 1.68 | -3.0% |
Price
| Price | $141.84 |
| Market Cap | $14.3B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 21.13% |
| Return on Invested Capital | 13.20% |
| Return on Assets | 13.16% |
| Gross Margin | 97.97% |
| Operating Margin | 23.38% |
| Net Margin | 20.91% |
Related companies: COO · ELAN · ICLR · RDY · SMMT · SNN
Explore sector: Healthcare · Biotechnology
More sections of NBIX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks